The three-dimensional structure of adeno-associated virus (AAV) serotype 6 (AAV6) was
determined using cryo-electron microscopy and image reconstruction and using X-ray …

Three recent approvals and over 100 ongoing clinical trials make adeno‐associated virus
(AAV)‐based vectors the leading gene delivery vehicles in gene therapy. Pharmaceutical …

Viruses can be engineered to efficiently deliver exogenous genes, but their natural gene
delivery properties often fail to meet human therapeutic needs. Therefore, engineering viral …

Interactions between viruses and the host antibody immune response are critical in the
development and control of disease, and antibodies are also known to interfere with the …

Recent clinical successes in gene therapy applications have intensified interest in using
adeno-associated viruses (AAVs) as vectors for therapeutic gene delivery. Although …

AAV gene therapy vectors have significant clinical promise, but serum neutralization poses a
challenge that must be overcome. We have examined the potential of conjugating the AAV …

Adeno-associated virus (AAV) has emerged as an attractive vector for gene therapy. AAV
vectors have successfully been utilized to promote sustained gene expression in a variety of …

We have demonstrated the potential of random peptide libraries displayed on adeno-
associated virus (AAV) 2 to select for AAV2 vectors with improved efficiency for cell type …

Adeno-associated virus (AAV) vectors are preeminent in emerging clinical gene therapies.
Generalizing beyond the most tractable genetic diseases will require modulation of cell …

AAV vectors poorly transduce Dendritic cells (DC), a feature invoked to explain AAV's low
immunogenicity. However, the reason for this non-permissiveness remained elusive. Here …